Top
image credit: Adobe Stock

Frequency to cut jobs after clinical trial setback

February 13, 2023

A spinout of the Massachusetts Institute of Technology, Frequency sought to develop treatments for hearing loss by regenerating lost hair cells in the inner ear, rather than turning to hearing aids or implants.

Both its lead drug FX-322 and FX-345, its follow-on candidate, were aimed at sensorineural hearing loss, which results from damage to sensory hair cells and is estimated to impact millions of individuals in the U.S.

Read More on Biopharma Dive